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Summary: The 2014-15 H1N1 outbreak in India has reportedly lead to 800 fatalities. The reported 
influenza hemagglutinin sequences from India indicate that these viruses contain amino acid 
changes linked to enhanced virulence and are potentially antigenically distinct from the current 
vaccine containing 2009 (Cal0709) H1N1 viral hemagglutinin. 
Between 2009-2012, the 2009 pandemic H1N1 (2009pdmH1N1) virus is estimated to have caused 
over 18,449 deaths across 214 countries worldwide (Cheng et al., 2012). Since the initial outbreak, 
the 2009pdmH1N1 has replaced the prior seasonal H1N1, and established itself in the human 
population. This is largely due to sequence evolution of the hemagglutinin (HA) protein, whose 
activity critically governs the receptor binding, fusion and transmission properties of the virus (Smith 
et al., 2009). 
The recent 2014-15 H1N1 outbreak in India has resulted in >8,000 cases with over 800 
deaths, although remains unclear if this is an underestimation. Anecdotal reports indicate that the 
majority of these cases involve young adults - a trend that is similar to the 1918 Spanish Flu 
pandemic when 50-100 million people died worldwide. One recent news report from India indicates 
that influenza genes sequenced from patient swab samples revealed no new mutations in the virus 
(http://indianexpress.com/article/cities/pune/silver-lining-no-mutation-of-h1n1-says-study/). 
Additionally, it was suggested the 2009pdmH1N1 outbreak strain - A/California/04/2009 - was 
responsible for the outbreak in India. 
Continuous surveillance of influenza viruses enables researchers to track viral evolution, 
understand amino acid sequences in key viral proteins governing their circulation, predict potential 
“outbreaks” and assist in the development of various “outreach” approaches to both treat as well 
as prevent further spread. Typically, influenza-genome data collected from field studies or research 
efforts are sequenced and submitted to GenBank and/or one or more specialized open-access 
databases. Open access databases such as National Center for Biotechnology Information (or NCBI) 
Influenza Virus Resource 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html)http://www.ncbi.nlm.nih.gov/genomes/FL
U/FLU.html, Influenza Research Database (http://www.fludb.org/) and EpiFlu 
(http://platform.gisaid.org/epi3/start ) facilitate sharing of viral genome sequences and encourage 
collaborative research world over. In addition to providing access to nucleotide and amino acid 
sequences, these specialized databases provide researchers additional information such as genetic 
markers (e.g. drug resistance, increased virulence etc.) and form the basis of epidemiological and 
clinical data and tools for analyzing the genomic sequences e.g. sequence comparison and 
alignment, phylogeny tree construction, epitope prediction and mapping. An analysis of the publicly 
available influenza databases from the recent outbreak in India suggests that influenza monitoring 
has not yet reached sufficient levels to enable real-time surveillance.  
Overall, there exists 15,173 H1N1 pdm HA sequences in the public sequence databases, out 
of which 4,213 represent full-length, non-redundant entries. Examination of the geography of the 
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isolated strains shows that the majority of the deposited influenza sequences come from US 
(38.4%), China (7.2%), United Kingdom (6.5%) and Singapore (6%). Unfortunately, India ranks low 
(14th) in this list, contributing less than 1.5% of sequences. Furthermore, despite the vastness of the 
Indian subcontinent, only two sequences have been deposited during 2014-15 from India, 
suggesting poor surveillance and potentially limiting the response to a deadly outbreak. 
Additionally, swine can also contribute to the emergence of novel H1N1 variants through the 
process of reverse zoonoses and thus should also be monitored. Despite the risk posed by these 
animals, the number of swine influenza sequences collected in the 2009-2015 period is insignificant 
with notably no swine influenza strains deposited from India. These numbers highlight the irregular, 
reactive nature of the influenza surveillance response.  
Although there are limited Indian-origin sequences available in the public database to make 
any causal inference on the perceived increased fatalities in India, examination of the 2014 Indian 
H1N1 sequences shows traits with potential cause for concern. Amino acid changes in specific 
positions in the receptor binding site (RBS) of 2009pdmH1N1 have been shown to impact glycan 
RBS specificity and have been linked to increased virulence and disease severity.  Among these 
changes, the Indian-origin strain A/India/6427/2014 contains amino acid changes T200A and D225N 
compared to the current vaccine 2009 H1N1 strain. The T200A amino acid change has been shown 
to improve human glycan receptor-binding of 2009pdmH1N1 HA (Xu et al., 2012b). The D225N 
mutation has been linked to increased virulence and disease severity in patients infected by the 
2009 pdm virus (Ruggiero et al., 2013). Importantly, a previous study showed that the D225N 
mutation in the context of H1 HA affected receptor binding and also decreased susceptibility to NA 
inhibitors (McKimm-Breschkin et al., 2013). It should be noted that the D225N mutation was 
previously linked to serious illness resulting in hospitalization or death (L'Vov D et al., 2010). The 
high population density in India, ease of person-to-person transmission and lack of effective 
treatment options create ample opportunities for this variant to sustain and become dominant. The 
severity of the current outbreak seems to correlate with this observation.   
Gene reassortment wherein segments of the genome are exchanged between different 
strains is another mechanism that drives rapid influenza evolution. Indeed, the previous three 
pandemics emerged as a result of gene reassortment. The 1957 H2N2 (Asian flu) pandemic emerged 
through reassortment between human H1N1 and avian H2N2. Similarly, the H3N2 (Hong Kong) 
pandemic was caused by a human-adapted H2N2 virus as it obtained avian H3 and PB1 genes 
through reassortment). The 2009 swine-origin H1N1 pandemic emerged as a result of reassortment 
between avian, human and swine influenza viruses. India houses billions of farmed birds and swine 
animals across the country. Combined with this, export of animals and challenges to farming 
infrastructure augment the risk of reassortment events. Although the 2014 Indian-origin strains 
appear to have not undergone reassortment, the involvement of gene reassortment in the current 
outbreak in India cannot be determined without full genome sequence information.  
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Since 2009, HAs of the 2009pdmH1N1 lineage have gradually acquired mutations in the H1 
antigenic sites (Sa, Sb, Ca & Cb) (Caton et al., 1982) (Fig. 1). Notably, strains carrying 7 antigenic-site 
mutations appeared in 2013, which has implications for re-evaluation of the H1N1 vaccine 
component (A/California/04/2009). Importantly, the mutation K166Q at the 'Sa' antigenic site 
discriminated strains that circulated before 2013 from those that circulated during 2014-15. While 
the majority of strains that circulated before 2013 possessed Lys at 169, >80% of the strains that 
circulated after 2013, including the two 2014 Indian isolates, possessed a Gln. Importantly, a 
previous study showed that a variation at 166 could lead to escape from neutralizing antibodies 
elicited by the current H1N1 vaccine component A/California/07/2009 (Linderman et al., 2014). The 
K166Q mutation may also exert an influence on the receptor binding property of the HA due to its 
close proximity to the receptor binding site (Fig. 2). Additionally, while the antigenic residues N129 
(Sa), G158 (Sa) and N159 (Sb) (Fig. 2) were observed at relatively lower, fluctuating frequencies 
before 2013, they continually increased in frequency and became more dominant after 2013. In 
summary, the set of mutations that characterize the 2014 Indian strain are T200A and D225N and 
K166Q. Additionally, as noted above antigenic residues (N129, G158, N159) are also important HA 
residue changes observed in the 2014 Indian derived HA. These extensive amino acid changes 
observed in 2014 Indian influenza HA contradict the recent reports by Indian news media on a lack 
of mutations observed in the H1N1 viruses in India. 
Given the global reach of influenza, there is an urgent need to develop a comprehensive and 
at least somewhat standardized response to influenza epidemic outbreaks.  Authorities and health 
officials should document outbreaks with limited delays. As was the case with the H7N9 outbreak, 
there needs to be genetic and phenotypic analysis of the virus and general dissemination of the data 
to ensure access to real-time information.  For many strains, only the HA gene is sequenced leaving 
the rest of the genome incomplete. This is because many of these efforts are part of research studies 
that focus on receptor binding or immune response. Additionally the cost of sequencing is still 
prohibitively expensive for many. All the above factors pose challenges for real-time surveillance.  
In the context of various outreach towards slowing or halting an epidemic outbreak, access 
to antivirals and vaccines both play a large part; thus a priority should be development of 
infrastructure to make, store, and distribute appropriate countermeasures.  In this case, stockpiling 
of antivirals for targeted administration can buy time to allow for a widespread vaccination 
campaign. Additionally, the development of a universal vaccine can go a long way in mitigating the 
risk of high mortality. 
One response to epidemic outbreaks is to identify vaccine strategies to abbreviate the time 
lag between advent of a novel virus strain and the manufacture of vaccine, such as through synthetic 
approaches (Dormitzer et al., 2013) or use of alternative vaccine formats, such as virus-like particles 
(Fries et al., 2013). An alternative approach may be through targeted use of prophylactic anti-virals.  
Modeling of such an approach for malaria has indicated that judicious use of artemisinin can affect 
spread (Peak et al., 2015).  Similar epidemiological modeling of influenza epidemic outbreaks may 
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allow for such strategies, such as potentially targeting high risk populations such as health care 
workers with a prophylactic long-lived antiviral to possibly mute outbreaks, allowing time for 
implementation of vaccine strategies. 
Even in the event of the absence of a successful vaccination strategy or the development of 
resistance to neuraminidase inhibitors, the use of antibody to treat influenza has some clinical 
experience to support efficacy. For example, a recent study evaluated the use of convalescent 
plasma in 93 patients with H1N1 2009 influenza in Hong Kong (Hung et al., 2011) In this prospective 
multi-center case control study, patients with severe influenza who were hospitalized and required 
intensive care unit support, were recruited and offered convalescent plasma containing influenza 
neutralizing antibody in addition to the standard of care with a neuraminidase inhibitor, either 
oseltamivir or zanamivir.  Mortality was significantly lower in the treatment groups who received 
convalescent plasma compared to the controls (20.0% vs. 54.8%, p=0.01).  To this end, there have 
been several reports of broadly neutralizing antibodies for influenza, which clearly neutralize 
influenza virus in vitro, provide complete protection after a single administration in vivo, and protect 
against multiple strains of influenza (Corti et al., 2011; Ekiert et al., 2009). 
In summary, the influenza outbreak in India should be further examined to further 
determine the virulence and potential threat of this virus. Improved surveillance and monitoring of 
the influenza outbreak will significantly enhance the options of how best we can manage outreach 
to both treat as well as prevent spread of the virus. 
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FIGURE LEGEND 
Fig. 1. Phylogenetic tree of 1,000 representative H1N1 HA amino acid sequences belonging to the 
2009 pdm lineage generated by Neighbor Joining method. Due to the sheer density of nodes and 
branches, only a handful of strains are labeled (by strain name and subtype). Clades are defined 
based on high bootstrap confidence values (>70%) at every node. Branches corresponding to the 
Indian H1N1 strains are highlighted in green. Scale bar indicates the number of nucleotide 
substitutions per site. The vast majority of the strains in clades I-III were isolated between 2009-
2013 whereas the strains in clades IV and V were isolated between 2010-2015. The Indian H1N1 
strains are clustered in clades IV and V except for a single strain that is part of clade II. 
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Fig. 2. Three-dimensional X-ray crystal structure of trimeric HA1 globular head of 
A/California/04/2009 in complex with human receptor LSTc (Xu et al., 2012a)(PDB: 3UBE). The 
view of the trimer is along axis perpendicular to 3-fold symmetry axis. The antigenic sites Sa, Sb, Ca 
and Cb are colored blue, red, magenta and green, respectively. The human receptor is represented 
in a stick format in tint color. The approximate locations of the antigenic sites mentioned in the text 
are marked on the structure.  
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